Novo Nordisk stock is oversold, but is the 70% collapse from its peak over?

Novo Nordisk stock closed at 38.71 on September 28, barely changed from the prior session’s 38.80. Yet an intraday recovery from an open of 38.40 shows buyers emerging at lower levels. Sellers still control the bigger picture, but the tension now defines the setup.

Key takeaways

• NVO daily RSI sits at 30.76, deep in oversold territory, while the daily trend remains unambiguously bearish.
• Price at 38.71 trades below all major moving averages — the 20-day EMA at 42.04, 50-day EMA at 44.28, and 200-day EMA at 46.88.
• The hourly chart shows stabilization rather than reversal, with RSI at a neutral 45.69 and price hovering near the EMA20.
• CagriSema delivered an estimated 12.4% body weight loss after 60 weeks in the Phase 3 REIMAGINE 5 trial, positioning it ahead of Eli Lilly’s tirzepatide.
• The stock has lost more than 70% of its value from the peak, leaving investors questioning what comes after the weight-loss franchise.

Daily Trend: Novo Nordisk Stock Remains in a Bearish Structure

The daily trend on Novo Nordisk stock remains unambiguously bearish. Price at 38.71 sits well below every major moving average, confirming an unbroken downtrend.

The 20-day EMA at 42.04, 50-day EMA at 44.28, and 200-day EMA at 46.88 all tower above current price. That stacked order is the textbook signature of a trend that has not turned yet, regardless of short-term wiggles. The system itself flags the daily regime as bearish, and the chart backs that label up.

Momentum Signals Flash Oversold

Momentum tells a slightly more nuanced story. The daily RSI14 sits at 30.76, deep in oversold territory. That reading does not guarantee a bounce, but it does suggest aggressive selling has stretched the rubber band.

Meanwhile, MACD remains negative. The line sits at -2.06 against a signal of -1.62, with a histogram of -0.44. The negative histogram confirms momentum is still pointed down, even if the RSI hints at exhaustion building underneath.

Volatility and Pivot Context

Bollinger Bands add context on volatility. The mid-band sits at 42.79, with the upper band at 48.59 and the lower band at 36.98. Price trades close to the lower band without breaking through it. This usually signals a stretched but not yet climactic move.

ATR14 at 1.14 shows daily ranges remain elevated, consistent with a market still digesting a sharp decline. On the pivot side, price hovers just above the daily pivot point of 38.61. Resistance sits at r1 39.00 and support at s1 38.33 — a narrow band that will likely decide the next short-term move.

Hourly Chart: Stabilization, Not Reversal

The hourly chart on Novo Nordisk stock shows stabilization rather than a genuine reversal. Price hovers near the EMA20 but remains below longer moving averages, with the regime labeled neutral rather than bullish.

Price at 38.72 sits almost exactly on the hourly EMA20 of 38.70. However, it remains below the EMA50 at 39.59 and far under the EMA200 at 43.16. The regime here is labeled neutral rather than bearish. In other words, the hourly chart is not confirming a reversal — it is simply pausing.

RSI14 on the hourly timeframe reads 45.69, a neutral level that neither supports aggressive buying nor confirms further selling. MACD has flipped slightly positive. The histogram sits at 0.11 versus a line of -0.19 and signal of -0.30. That small crossover suggests short-term momentum is trying to turn, though the move is thin.

Bollinger Bands on the hourly are tight, ranging from 38.26 to 38.86. Price sitting near the pivot point of 38.70 shows the market is essentially undecided at this exact level.

Therefore, the daily and hourly timeframes are not fully aligned. The daily trend is bearish and unbroken. The hourly trend is neutral, showing a pause rather than a genuine reversal. This is a common pattern after sharp declines: short-term stabilization inside a longer downtrend.

15-Minute Chart: Buyers Testing Resistance

On the 15-minute chart, short-term buyers appear more active. However, this micro timeframe is useful only for timing entries or exits. It does not define the broader bias on Novo Nordisk stock.

RSI14 at 54.5 leans mildly bullish. Price at 38.72 sits above both the EMA20 at 38.67 and EMA50 at 38.62. It remains below the EMA200 at 39.60. MACD is essentially flat, with the line and signal both near 0.05 and a histogram of zero. Momentum here is undecided at the micro level.

The 15m pivot resistance at r1 38.76 is close to current price, meaning execution traders are watching whether this level breaks or holds.

Bullish Scenario for Novo Nordisk Stock

A bullish case for Novo Nordisk stock would require confirmation across timeframes, not just a single bounce. The minimum technical threshold is a sustained close above the hourly EMA50 at 39.59. It would need to be followed by a daily close above the 20-day EMA at 42.04.

Such a move would meaningfully weaken the current bearish structure. RSI reclaiming the 50 level on the daily chart would also help validate that buyers, not just short covers, are stepping in.

Fundamental Catalysts Supporting a Recovery

News flow offers some fundamental support for this scenario. Novo Nordisk reported results from its Phase 3 REIMAGINE 5 trial. CagriSema 1 mg/1 mg delivered an estimated 12.4% body weight loss after 60 weeks. The company positioned this result ahead of Eli Lilly’s tirzepatide.

Separately, at its September 2026 Capital Markets Day, the company outlined pipeline sales targets above $23 billion by 2035. It also said it aims to launch more than five new products. CEO Mike Doustdar signaled openness to deals beyond the core weight-loss franchise.

If the market starts pricing in that diversification story, it could provide the sentiment shift needed to support a technical recovery.

Bearish Scenario and What Would Invalidate the Bounce

The bearish case remains the path of least resistance for Novo Nordisk stock until proven otherwise. A rejection near the hourly resistance zone around 38.76–39.00 would be the first signal. A subsequent close below the pivot at 38.61 and s1 support at 38.33 would reopen the door. The next target would be the lower Bollinger band at 36.98.

If daily RSI rolls back below 40 after this brief stabilization, that would confirm sellers have reasserted control.

The fundamental backdrop leaves room for that outcome. One report noted the stock has lost more than 70% of its value from the peak. This has prompted investors to press management on what comes after the weight-loss franchise. Another highlighted a decline of over 60% across the past two years.

The search for a “second act” remains an open question rather than a settled one. Until the market sees tangible evidence that new pipeline targets translate into revenue, skepticism is likely to persist. This skepticism around the stock’s structural growth story would keep a lid on any rally attempts.

Closing Take: Novo Nordisk Stock at a Crossroads

Novo Nordisk stock sits at a genuine crossroads between timeframes. The daily trend remains bearish. The hourly chart is stabilizing without reversing. The 15-minute chart shows buyers probing resistance. This layered disagreement argues for caution rather than conviction.

Volatility, as measured by the daily ATR of 1.14, remains elevated enough that swings in both directions should be expected. RSI is oversold on the daily chart but neutral on the hourly. Fundamental news flow itself is split between promising trial data and unresolved growth questions. The near-term path looks uncertain.

Positioning here should account for a key possibility. This may be a pause within a downtrend rather than its end. That holds true at least until price action on the daily chart proves otherwise.

FAQ

Is Novo Nordisk stock oversold right now?

Yes. The daily RSI14 sits at 30.76, which is deep in oversold territory. However, an oversold reading does not guarantee a bounce. It simply indicates the pace of selling has been aggressive.

What are the key support and resistance levels for NVO?

Immediate support sits at the daily pivot s1 of 38.33, with the lower Bollinger band at 36.98 as the next major floor. Resistance is clustered between the hourly r1 at 38.76 and the daily r1 at 39.00. The hourly EMA50 at 39.59 is the next major hurdle.

What would confirm a bullish reversal in Novo Nordisk stock?

A sustained close above the hourly EMA50 at 39.59 would be the first step. It would need to be followed by a daily close above the 20-day EMA at 42.04. RSI reclaiming 50 on the daily chart would add further validation.

What fundamental factors are affecting Novo Nordisk stock?

CagriSema delivered a 12.4% body weight loss result in the Phase 3 REIMAGINE 5 trial. The company outlined pipeline targets above $23 billion by 2035. However, the stock has lost over 70% from its peak. Investors remain skeptical about the growth story beyond weight loss.

{"@context":"","@type":"FAQPage","mainEntity":[{"@type":"Question","name":"Is Novo Nordisk stock oversold right now?","acceptedAnswer":{"@type":"Answer","text":"Yes. The daily RSI14 sits at 30.76, which is deep in oversold territory. However, an oversold reading does not guarantee a bounce. It simply indicates the pace of selling has been aggressive."}},{"@type":"Question","name":"What are the key support and resistance levels for NVO?","acceptedAnswer":{"@type":"Answer","text":"Immediate support sits at the daily pivot s1 of 38.33, with the lower Bollinger band at 36.98 as the next major floor. Resistance is clustered between the hourly r1 at 38.76 and the daily r1 at 39.00. The hourly EMA50 at 39.59 is the next major hurdle."}},{"@type":"Question","name":"What would confirm a bullish reversal in Novo Nordisk stock?","acceptedAnswer":{"@type":"Answer","text":"A sustained close above the hourly EMA50 at 39.59 would be the first step. It would need to be followed by a daily close above the 20-day EMA at 42.04. RSI reclaiming 50 on the daily chart would add further validation."}},{"@type":"Question","name":"What fundamental factors are affecting Novo Nordisk stock?","acceptedAnswer":{"@type":"Answer","text":"CagriSema delivered a 12.4% body weight loss result in the Phase 3 REIMAGINE 5 trial. The company outlined pipeline targets above $23 billion by 2035. However, the stock has lost over 70% from its peak. Investors remain skeptical about the growth story beyond weight loss."}}]}

Article produced with the assistance of artificial intelligence and reviewed by the editorial team.